Drug giant GlaxoSmithKline (GSK) is launching a shake-up of its sales and marketing incentives as Chinese officials continue a probe into bribery allegations.GSK is scrapping individual targets for its sales staff and replacing them with a scheme rewarding technical knowledge, service quality and the overall performance of the group.The company also plans to stop paying healthcare professionals to promote its drugs or to attend medical conferences to fend off claims about potential conflicts of interest.It plans to launch the new compensation system in all the countries it trades in by early 2015.Chinese police are investigating the company after accusing it of channeling up to £314m through travel agents to bribe doctors and hospital officials to boost sales, according to state news reports.GSK said the moves were designed to increase transparency, rather than being directly linked to the Chinese issues.Chief Executive Andrew Witty said they follow other changes in the last five years including steps to boost access to medicines in developing countries and to make clinical trial data clearer.Witty said: "These measures are designed to bring greater clarity and confidence so that whenever we talk to a doctor, nurse or other prescriber, it is patients' interests that always come first."We have an important role to play in providing doctors with information about our medicines, but this must be done clearly, transparently and without any perception of conflict of interest."A GSK spokeswoman added: "The Chinese investigation is ongoing and we're co-operating fully with the authorities."GSK shares fell 19p to 1570p at 15:36 in London.PW